[Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Hiperparatiroidismo en pacientes con baja densidad mineral ósea tratados con ácido zoledrónico o denosumab.
    • Source:
      Publisher: Elsevier España Country of Publication: Spain NLM ID: 0376377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1578-8989 (Electronic) Linking ISSN: 00257753 NLM ISO Abbreviation: Med Clin (Barc) Subsets: MEDLINE
    • Publication Information:
      Publication: <2009- > : Madrid : Elsevier España
      Original Publication: Barcelona : Ediciones Doyma, S.A.
    • Subject Terms:
      Denosumab*/therapeutic use ; Denosumab*/adverse effects ; Zoledronic Acid*/therapeutic use ; Zoledronic Acid*/adverse effects ; Bone Density Conservation Agents*/therapeutic use ; Bone Density*/drug effects ; Osteoporosis*/drug therapy ; Osteoporosis*/epidemiology ; Osteoporosis*/etiology; Humans ; Retrospective Studies ; Female ; Male ; Aged ; Middle Aged ; Glomerular Filtration Rate ; Parathyroid Hormone/blood ; Diphosphonates/therapeutic use ; Hyperparathyroidism ; Aged, 80 and over ; Imidazoles/therapeutic use ; Imidazoles/adverse effects ; Bone Diseases, Metabolic/epidemiology ; Bone Diseases, Metabolic/etiology ; Prevalence
    • Abstract:
      Objective: To analyze the prevalence of hyperparathyroidism in patients treated with zoledronic acid (ZA) or denosumab, its relationship with other parameters and how it affects on bone mineral density (BMD) evolution.
      Methods: Retrospective observational study in patients with osteoporosis or osteopenia and high risk of fracture, who have received denosumab or ZA for at least two years. Patients diagnosed with hyperparathyroidism or glomerular filtration rate <30ml/min at baseline visit were excluded from the study.
      Results: Ninety patients (ZA: 54.44%) were included. 18.36% of ZA-treated patients had elevated PTH levels at some time compared to 36.58% denosumab-treated patients (p>0.05). Patients with persistently elevated PTH were 6.13% in the AZ group and 19.51% in the denosumab group (p<0.04). We found a statistically significant inverse association between elevated PTH levels, glomerular filtration rate (p=0.007), and albumin-corrected calcium (p <0.001). We did not find an association between hyperparathyroidism and BMD evolution.
      Conclusions: A high incidence of hyperparathyroidism was observed in patients treated with AZ and especially denosumab. Hyperparathyroidism correlated inversely with glomerular filtration rate and albumin-corrected calcium. Elevated PTH does not appear to affect short-term bone mineral density evolution.
      (Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)
    • Contributed Indexing:
      Keywords: Albumin-corrected calcium; Calcio corregido por albúmina; Denosumab; Filtrado glomerular; Fósforo; Glomerular filtration rate; Hiperparatiroidismo; Hyperparathyroidism; Phosphorus; Zoledronic acid; Ácido zoledrónico
    • Accession Number:
      4EQZ6YO2HI (Denosumab)
      6XC1PAD3KF (Zoledronic Acid)
      0 (Bone Density Conservation Agents)
      0 (Parathyroid Hormone)
      0 (Diphosphonates)
      0 (Imidazoles)
    • Publication Date:
      Date Created: 20241009 Date Completed: 20241212 Latest Revision: 20241217
    • Publication Date:
      20241217
    • Accession Number:
      10.1016/j.medcli.2024.07.020
    • Accession Number:
      39384494